ARS Pharmaceuticals (SPRY) Amortizatization of Intangibles (2022 - 2026)

ARS Pharmaceuticals (SPRY) has 5 years of Amortizatization of Intangibles data on file, last reported at $990000.0 in Q1 2026.

• For the quarter ending Q1 2026, Amortizatization of Intangibles fell 49.52% year-over-year to $990000.0; the trailing twelve-month figure through Mar 2026 stood at $4.6 million (down 59.34% YoY), and the FY2025 full-year result was $5.5 million, down 23.86% from the prior year.
• Amortizatization of Intangibles slipped to $990000.0 in Q1 2026, from $1.0 million in the prior quarter.
• In the past five years, Amortizatization of Intangibles ranged from a high of $5.9 million in Q2 2024 to a low of -$2.0 million in Q1 2024.
• A 5-year average of $514571.4 and a median of $996500.0 in 2025 frame the typical range for Amortizatization of Intangibles.
• Across the five-year window, Amortizatization of Intangibles tumbled 705.96% in 2023 and jumped 434.7% in 2024, its largest moves.
• Tracing SPRY's Amortizatization of Intangibles over 5 years: stood at $285000.0 in 2022, then slumped by 705.96% to -$1.7 million in 2023, then soared by 189.4% to $1.5 million in 2024, then tumbled by 35.04% to $1.0 million in 2025, then slipped by 1.3% to $990000.0 in 2026.
• Business Quant data shows SPRY's Amortizatization of Intangibles at $990000.0 in Q1 2026, $1.0 million in Q4 2025, and $1.1 million in Q3 2025.